;
Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Access Pharmaceuticals, Norgine deal

    Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Norgine B.V., Amsterdam, the Netherlands Business: Other Access granted Norgine exclusive rights to develop and commercialize Access' MuGard for oral mucositis in …

    Published on 9/8/2014
  • Alder, Bristol-Myers deal

    Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Bothell, Wash. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Autoimmune Alder said Bristol-Myers Squibb discontinued development of clazakizumab (BMS-945429) …

    Published on 9/8/2014
  • Ascend Therapeutics, Aeterna Zentaris deal

    Ascend Therapeutics US LLC, Herndon, Va. Aeterna Zentaris Inc. (TSX:AEZ;NASDAQ:AEZS), Quebec City, Quebec Business: Endocrine/Metabolic Aeterna Zentaris and Ascend will co-promote Ascend's EstroGel transdermal estrogen …

    Published on 9/8/2014
  • Bayer, Boston Scientific deal

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Boston Scientific Corp. (NYSE:BSX), Natick, Mass. Business: Cardiovascular Medical device company Boston Scientific completed its purchase of Bayer's interventional device …

    Published on 9/8/2014
  • Biolipox, Boehringer Ingelheim deal

    Biolipox AB, Stockholm, Sweden Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Neurology, Inflammation Orexo AB (SSE:ORX; OTCQX:ORXOY, Uppsala, Sweden) said Boehringer returned all rights to OX-MPI, a …

    Published on 9/8/2014
  • BioServe, ReproCell deal

    BioServe Biotechnologies Ltd., Beltsville, Md. ReproCell Inc. (JASDAQ:4978), Yokohama, Japan Business: Supply/Service ReproCell acquired human tissue supplier BioServe for an undisclosed sum. ReproCell said it gains …

    Published on 9/8/2014
  • Buck Institute, Mount Tam deal

    Buck Institute for Research on Aging, Novato, Calif. Mount Tam Biotechnologies Inc., Novato, Calif. Business: Autoimmune The non-profit Buck Institute granted newco Mount Tam exclusive, worldwide rights to a portfolio …

    Published on 9/8/2014
  • Calico, AbbVie deal

    Calico LLC, South San Francisco, Calif. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Neurology, Cancer Calico and AbbVie will provide up to $1.5 billion to discover, develop and commercialize treatments for age-…

    Published on 9/8/2014
  • Cellectis, Takara Bio deal

    Cellectis S.A. (Euronext:ALCLS), Paris, France Takara Bio Inc. (Tokyo:4974), Shiga, Japan Business: Gene/Cell therapy Cellectis sold its Cellectis AB subsidiary to Takara. The subsidiary is focused on applications of …

    Published on 9/8/2014
  • Huya, Changzhou Center for Biotech Development deal

    Huya Bioscience International LLC, San Diego, Calif. Changzhou Center for Biotech Development, Changzhou, China Business: Pharmaceuticals Huya will have the first opportunity to evaluate R&D projects supported by the …

    Published on 9/8/2014
  • Infinity, AbbVie deal

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer Infinity granted AbbVie rights to co-develop and co-commercialize duvelisib (IPI-145) in the U.S. and…

    Published on 9/8/2014
  • InSite, Inspire deal

    InSite Vision Inc. (OTCBB:INSV), Alameda, Calif. Inspire Pharmaceuticals Inc., Durham, N.C. Business: Infectious, Ophthalmic In June, Akorn Inc. (NASDAQ:AKRX, Lake Forest, Ill.) paid InSite $6 million in exchange for a …

    Published on 9/8/2014
  • InterMune, Roche deal

    InterMune Inc. (NASDAQ:ITMN), Brisbane, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Pulmonary InterMune disclosed in an SEC filing that six other companies expressed interest in a deal before Roche …

    Published on 9/8/2014
  • Isis Pharmaceuticals, Biogen Idec deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Business: Neurology Isis received a $2 million milestone payment from Biogen Idec under a 2012 deal under which the…

    Published on 9/8/2014
  • Leica Biosystems, Bristol-Myers deal

    Leica Biosystems Inc., Nussloch, Germany Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Diagnostic Leica Biosystems will develop automated tissue-based companion diagnostic tests to aid in selecting …

    Published on 9/8/2014
  • Ligand, Marinus deal

    Ligand Pharmaceuticals Inc. (NASDAQ:LGND), La Jolla, Calif. Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), New Haven, Conn. Business: Neurology, Drug delivery Marinus will use the Captisol drug formulation technology from …

    Published on 9/8/2014
  • Merus Labs International, Dacha Strategic Metals deal

    Merus Labs International Inc. (TSX:MSL;NASDAQ:MSLI), Toronto, Ontario Dacha Strategic Metals Inc., Toronto, Ontario Business: Genitourinary Dacha purchased 4.2 million Merus shares for C$7 million ($6.4 million). The …

    Published on 9/8/2014
  • Nicox, Bausch + Lomb deal

    Nicox S.A. (Euronext:COX), Sophia Antipolis, France Bausch + Lomb Inc., Rochester, N.Y. Business: Ophthalmic Nicox exercised its option to co-promote latanoprostene bunod (NCX 116) in the U.S. under a 2010 deal with the…

    Published on 9/8/2014
  • Noven, Novartis deal

    Noven Pharmaceuticals Inc., Miami, Fla. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Drug delivery, Endocrine/Metabolic Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530, Tosu, Japan)and Novartis dissolved …

    Published on 9/8/2014
  • Opus Bio, Miltenyi Biotec deal

    Opus Bio Inc., Greenwich, Conn. Miltenyi Biotec GmbH, Bergisch Gladbach, Germany Business: Gene/Cell therapy Lentigen Corp. changed its name to Opus Bio and sold its lentiviral vector manufacturing business and related …

    Published on 9/8/2014
  • Photocure, Salix deal

    Photocure ASA (OSE:PHO), Oslo, Norway Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Business: Diagnostic Photocure said it and Salix mutually agreed to terminate a 2010 deal granting Salix exclusive, worldwide…

    Published on 9/8/2014
  • Protein Sciences, Liomont deal

    Protein Sciences Corp., Meriden, Conn. Laboratorios Liomont S.A. de C.V., Mexico City, Mexico Business: Infectious Protein Sciences granted Liomont exclusive rights to manufacture and commercialize Protein Sciences' …

    Published on 9/8/2014
  • Regulus, Biogen Idec deal

    Regulus Therapeutics Inc. (NASDAQ:RGLS), San Diego, Calif. Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Business: Autoimmune Regulus partnered with Biogen Idec to identify microRNA biomarkers in blood from multiple …

    Published on 9/8/2014
  • Reinnervate, ReproCell deal

    Reinnervate Ltd., Sedgefield, U.K. ReproCell Inc. (JASDAQ:4978), Yokohama, Japan Business: Supply/Service ReproCell acquired Reinnervate for an undisclosed sum. ReproCell plans to combine Reinnervate's Alvetex range of …

    Published on 9/8/2014
  • RESprotect, RedHill deal

    RESprotect GmbH, Dresden, Germany RedHill Biopharma Ltd. (Tel Aviv:RDHL;NASDAQ:RDHL), Ramat-Gan, Israel Business: Cancer RedHill received a one-year option from RESprotect to acquire exclusive, worldwide rights to RP101…

    Published on 9/8/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993